Business Unit
BioTech & Pharma
Biosimilars, pharmaceutical robotics, orphan drugs and innovative technologies for the healthcare sector.
Serichim
Development of biosimilar insulins (Detemir and Degludec) in partnership with ICGEB (International Centre for Genetic Engineering and Biotechnology). Portfolio of 9 patents in biotechnology, chemical processes and active pharmaceutical ingredients (APIs). The global biosimilar insulin market will reach €8.3 billion by 2030 with 21.5% CAGR.
ChemoMaker®
Patented pharmaceutical robot (EU, US, China) that automates chemotherapy preparation in hospital pharmacies. 95% of hospitals still manually prepare these drugs. ChemoMaker® eliminates staff exposure to cytotoxic substances, increases productivity and ensures precise dosing. Three revenue streams: device sales, cartridge sales, technical support.
Orphan Drugs
Hospital distribution of orphan drugs for rare diseases through hospital tender processes. In 2024-2025, 7 tenders awarded for Miglustat. In 2025, iBugo launched with 5 tenders awarded. The Italian rare disease market is worth €1.98 billion today, projected to reach €4.8 billion by 2030 (11.7% CAGR).
LOHCATE Srl
Founded in October 2025 to commercialize an innovative hydrogen release technology developed within the group. Received €1 million in EU project funding and has already attracted interest from Fincantieri for naval sector applications. Represents the latest development in the deep tech portfolio.
Focus: ChemoMaker®
The Robot that Protects Nurses
Every day in hospitals, nurses and pharmacists manually prepare highly toxic chemotherapy drugs. ChemoMaker® completely automates this process, eliminating exposure to cytotoxic substances.
The new CSTD (Closed System Transfer Device) version, launched in 2025, is completely sealed and requires no structural modifications to the pharmacy, removing the main barrier to adoption.
Real customers in Italian hospitals confirm: "greater safety for staff and increased productivity".